Clinical Trials

In preclinical and clinical trials, entinostat has exhibited a wide range of anti-tumor activity, alone or in combination with other therapies.

Study: ENCORE 601
Title: A Phase 1B/2, Open-label, Dose Escalation Study of Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Non-small Cell Lung Cancer or Melanoma

Study: ECOG-ACRIN E2112
Title: A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer
View more information on this study at ClinicalTrials.gov

Study: J1353
Title: A Randomized Phase 2 Study of Epigenetic Priming With Azacitidine and Entinostat Prior to Nivolumab in Subjects With Recurrent Metastatic Non-Small Cell Lung Cancer

Study: NCI-7870
Title: Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination With the Histone Deacetylase Inhibitor Entinostat in Patients With Metastatic Renal Cell Carcinoma

Study: NCI-9844
Title: A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab in Combination With Ipilimumab in Advanced Solid Tumors

Study: NCI 8871
Title: Phase 1 Trastuzumab Cohort Study of Entinostat, Lapatinib and Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab Has Failed

Study: ENCORE 301 (Completed)
Title: A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane +/- Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer, Progressing on Treatment With a Non-Steroidal Aromatase Inhibitor